You are here

Positive Phase III Results for Linalidomide (Revlimid) in Asymptomatic Myeloma

Combo therapy with dexamethasone improves 3-year survival (August 1)

Positive results have been reported from a phase III study that evaluated lenalidomide (Revlimid, Celgene) in combination with dexamethasone followed by lenalidomide maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma. The new findings were published in the August 1 issue of the New England Journal of Medicine.

Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10%-per-year risk of progression to symptomatic disease during the first 5 years.

After a median follow-up period of 40 months, the median time to progression to symptomatic disease — the study’s primary endpoint —was significantly longer in the treatment group compared with the observation group (not reached vs. 21 months, respectively; hazard ratio [HR] = 0.18; P P = 0.03). A partial response was observed in 79% of the patients in the treatment group during induction, and in 90% during the maintenance phase.

The most common grade 3 adverse events (AEs) in the treatment arm included infection (6%), asthenia (6%), neutropenia (5%), and rash (3%). No grade 4 AEs were reported. One patient had a grade 5 AE, reported as a respiratory infection.

Sources: Celgene; August 1, 2013; and NEJM; August 1, 2013.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market